上海萊士(002252.SZ):發行股份購買資產所涉股份登記申請受理確認
格隆匯3月17日丨上海萊士(002252.SZ)公佈,公司於2019年12月25日收到中國證監會下發的《關於核准上海萊士血液製品股份有限公司向Grifols, S.A.發行股份購買資產的批覆》(證監許可[2019]2863號)。
公司在此次發行股份購買資產的實施前置程序全部滿足後積極開展標的資產交割工作,此次發行股份購買資產之標的資產Grifols Diagnostic Solutions Inc.(“標的公司”或“GDS”)45%的股權過户手續已完成,公司現持有標的公司45%股權。具體內容詳見公司於2020年3月13日披露的相關公告。
2020年3月17日,中國證券登記結算有限責任公司深圳分公司出具《股份登記申請受理確認書》《上市公司股份未到帳結構表》《合併普通賬户和融資融券信用賬户前10名明細數據表》,中國證券登記結算有限責任公司深圳分公司已於2020年3月17日受理公司非公開發行新股登記申請材料,相關股份登記到賬後將正式列入上市公司的股東名冊。公司此次非公開發行新股數量約17.6617億股(其中限售流通股數量約17.6617億股),非公開發行後公司股份數量約67.4079億股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.